Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report

Rationale: For advanced non-small-cell lung cancer (NSCLC), targeted therapy and chemoradiotherapy are recommended as the first-line treatment. For patients with a performance status (PS) score over 2 and without gene mutation, however, only supportive treatment is provided and survival time is extremely short. We believe that more can be done to improve the patient's survival time and their quality of life. Patient concerns and diagnoses: A 65-year-old female came to our hospital due to “cough and pain and lack of movement in the left leg”. The diagnosis was advanced wild gene-type lung adenocarcinoma and PS score over 2. Interventions and outcomes: She was treated in our clinic with apatinib and erlotinib and has had no progression of the disease for 15.4 months. Except for the presence of hand-foot syndrome and diarrhea, no other serious adverse reactions were seen. Lessons: For patients in poor physical condition and unacceptable of chemo-radiotherapy, apatinib combined with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is a safe and effective therapeutic method for advanced wild gene-type NCSCL.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Related Links:

In the palliative care of patients with non-small cell lung cancer (NSCLC), bronchial hypersecretion (bronchorrhea) may cause additional dyspnea and impaired quality of life. Bronchorrhea is defined as mostly aqueous sputum production with a volume of> 100ml / 24 hours. Various treatment options have been described in case reports and small series, including the use of tyrosine kinase inhibitors such as gefitinib and erlotinib, somatostatin analogues (octreotide), macrolide antibiotics, anti-inflammatory drugs (indomethacin, corticosteroids) and anticholinergics.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
This is a nation ‐wide multicenter 10‐year cross‐sectional study in China. This paper tried to objectively examine the symptoms and physical signs in lung cancer patients, and determine whether lung cancer symptoms were independently associated with diagnosis. We found that the symptoms and physical signs were  associated with stage and pathologic diagnosis of NSCLC. AbstractBackgroundMost lung cancer patients are diagnosed after the onset of symptoms. However, whether the symptoms of lung cancer were independently associated with the diagnosis of lung cancer is unknown, especially in the Chinese population...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
In conclusion, we showed hypermethylation of CpGs as a novel mechanism of action for DNMTi agents and identified 638 hypermethylated molecular targets (CpGs) common to decitabine and azacytidine therapy. These novel results suggest that hypermethylation of CpGs should be considered when predicting the DNMTi responses and side effects in cancer patients. Introduction DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating the genome, with an aim to understand the role of DNA methylation in multiple processes (e.g., X-chromosome inactivation and DNA imprinting) and as an anti-ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Rationale: Mutation p.A289V involving extracellular region of epidermal growth factor receptor (EGFR) exon 7 has not yet been reported in nonsmall cell lung cancer (NSCLC). Studies have shown p.A289V mutation responding to tyrosine kinase inhibitors (TKIs) in glioblastoma cell lines suggesting the point mutation as a potential therapeutic target. However, sufficient evidence of the effect of TKI treatment on the p.A289V mutation involved in NSCLC is not available. Patient concerns: An 80-year-old nonsmoker male with lung mass was suffering from severe bone pain. Diagnosis: Needle biopsy and positron emitted tomogra...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
This study aimed to determine the different delays in the management of lung cancers through a retrospective descriptive and analytical study on 131 hospitalized cases in service between April 2014 and January 2017. Management delays were estimated from the date of the first symptom described by the patient (D1s), the first contact with health care provider (1Cs), then hospitalization (DH) and finally to the histological confirmation of the diagnosis (C Hist) before the start of treatment (D ttt).Among the patients included in our work, 90.8% were men, 87.8% were chronic smokers. The mean age was 61 years; chest pain was t...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
CONCLUSIONS: AMG 337 showed antitumor activity in MET-amplified G/GEJ/E adenocarcinoma but not in MET-amplified non-small-cell lung cancer. PMID: 30366938 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
In conclusion, the administration of postoperative NSAIDs was related to longer OS and PFS in NSCLC patients with postoperative fever.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Authors: Yamaguchi T, Gotoh Y, Hattori H, Katsuno H, Imaizumi K Abstract A previous randomized phase II study in patients with non-small cell lung cancer (NSCLC) identified that combination treatment with erlotinib plus bevacizumab prolonged progression-free survival compared with erlotinib alone. However, combination bevacizumab and erlotinib treatment generally increased the risk of severe adverse events, including hemorrhage, thrombosis, fistula formation and gastrointestinal perforation. The present report describes two patients with NSCLC harboring epidermal growth factor receptor (EGFR) mutations, who experie...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
We present a patient with epidermal growth factor receptor (EGFR)-mutant-NSCLC who developed metastatic SCLC after initial therapy with second-generation EGFR-tyrosine kinase inhibitor, afatinib. A 65-year-old male non-smoker was diagnosed with adenocarcinoma of the right lung, stage IVA (M1a). Due to tumor positivity for EGFR-Exon 19 deletion, the patient was started on oral afatinib, which resulted in a partial response. After ten months of treatment, he presented in the office with abdominal pain, distension, weight loss and jaundice. He had diffuse skeletal and hepatic metastases on PET/CT scan with interval progressio...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
AbstractImmune checkpoint inhibitors (ICIs) are becoming a standard therapy for non-small-cell lung cancer in the advanced stage. As these ICIs become widely available in clinical practice, immune-related adverse effects will become more common. Here we report a patient with lung adenocarcinoma who was treated with nivolumab and developed obstruction because of biliary inflammation. A 63-year-old Japanese man having lung adenocarcinoma with pleural dissemination complained of epigastric pain on the fifth cycle of nivolumab. Computed tomography showed wall thickening at the lower part of the bile duct and cholecystitis. End...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Hospitals | Internal Medicine | Lessons | Lung Cancer | Non-Small Cell Lung Cancer | Pain | Tarceva